December 8, 2025Blood

Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Validation of new genomic staging reveals renal dysfunction impacts survival in multiple myeloma.

High-risk multiple myeloma identified in 25.2% patients based on new consensus criteria.
Among those with normal renal function, 29.5% met high-risk criteria due to specific genomic features.
Observational analysis across diverse treatment regimens demonstrated a median overall survival of 75 months.
Validation emphasizes genomic staging's role, although further refinement is needed for patients with renal dysfunction.

Kastritis et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark